Metastamirs: A stepping stone towards improved cancer management

Nature Reviews Clinical Oncology

Volumn 8, Issue 2, 2011, Pages 75-84

  White, Nicole M A ^a   Fatoohi, Eman ^a   Metias, Maged ^a   Jung, Klaus ^b   Stephan, Carsten ^c   Yousef, George M ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Berlin Institute for Urologic Research   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LET 7; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 15A; MICRORNA 16; MICRORNA 200; MICRORNA 21; MICRORNA 221; MICRORNA 96; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; BLADDER CANCER; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DISEASE MARKER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE INTERACTION; HUMAN; LIVER CELL CARCINOMA; LIVER PROTECTION; LUNG NON SMALL CELL CANCER; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RNA ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS;

EID: 79551602747     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.173     Document Type: Review

References (137)

1. Yilmaz, M., Christofori, G. & Lehembre, F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol. Med. 13, 535-541 (2007).
2. Yoshida, B. A., Sokoloff, M. M., Welch, D. R. & Rinker-Schaeffer, C. W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Natl Cancer Inst. 92, 1717-1730 (2000).
3. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007).
4. Tavazoie, S. F. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152 (2008).
5. Wiemer, E. A. The role of microRNAs in cancer: no small matter. Eur. J. Cancer 43, 1529-1544 (2007).
6. Hurst, D. R., Edmonds, M. D. & Welch, D. R. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 69, 7495-7498 (2009).
7. Li, J. et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 15, 3998-4008 (2009).
8. Slaby, O. et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72, 397-402 (2007).
9. Yan, L. X. et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14, 2348-2360 (2008).
10. Zhu, S. et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18, 350-359 (2008).
11. Zhu, S., Si, M. L., Wu, H. & Mo, Y. Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328-14336 (2007).
12. Frankel, L. B. et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283, 1026-1033 (2008).
13. Sasayama, T., Nishihara, M., Kondoh, T., Hosoda, K. & Kohmura, E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int. J. Cancer 125, 1407-1413 (2009).
14. valastyan, S. et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046 (2009).
15. Tsai, W. C. et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49, 1571-1582 (2009).
16. Fabbri, M. et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA 104, 15805-15810 (2007).
17. Zhao, J. J. et al. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115, 2630-2639 (2010).
18. Gebeshuber, C. A., Zatloukal, K. & Martinez, J. MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 10, 400-405 (2009).
19. Sotiropoulou, G., Pampalakis, G., lianidou, E. & Mourelatos, Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15, 1443-1461 (2009).
20. Akao, Y., Nakagawa, Y. & Naoe, T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 26, 311-320 (2007).
21. Xia, H. et al. MicroRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res. 1269, 158-165 (2009).
22. Kong, W. et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 28, 6773-6784 (2008).
23. Tie, J. et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 6, e1000879 (2010).
24. Peter, M. E. Regulating cancer stem cells the miR way. Cell Stem Cell 6, 4-6 (2010).
25. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
26. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495 (2009).
27. Chan, J. A., Krichevsky, A. M. & Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029-6033 (2005).
28. Meng, F. et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007).
29. Asangani, I. A. et al. MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27, 2128-2136 (2008).
30. Si, M. L. et al. MiR-21-mediated tumor growth. Oncogene 26, 2799-2803 (2007).
31. Wang, P. et al. MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 69, 8157-8165 (2009).
32. Chang, J. et al. MiR-122, a mammalian liverspecific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1, 106-113 (2004).
33. Girard, M., Jacquemin, E., Munnich, A., Lyonnet, S. & Henrion-Caude, A. MiR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 48, 648-656 (2008).
34. Murakami, Y. et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537-2545 (2006).
35. Kutay, H. et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem. 99, 671-678 (2006).
36. Fornari, F. et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 69, 5761-5767 (2009).
37. Coulouarn, C., Factor, v. M., Andersen, J. B., Durkin, M. E. & Thorgeirsson, S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536 (2009).
38. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28, 341-347 (2010).
39. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582-589 (2008).
40. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008).
41. Korpal, M. & Kang, Y. The emerging role of miR-200 family of microRNAs in epithelialmesenchymal transition and cancer metastasis. RNA Biol. 5, 115-119 (2008).
42. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910-14914 (2008).
43. Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907 (2008).
44. Paterson, E. L. et al. The microRNA-200 family regulates epithelial to mesenchymal transition. ScientificWorldJournal 8, 901-904 (2008).
45. Dykxhoorn, D. M. et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 4, e7181 (2009).
46. Yousef, G. M. MicroRNAs: a new frontier in kallikrein research. Biol. Chem. 389, 689-694 (2008).
47. Zhang, H., Li, Y. & Lai, M. The microRNA network and tumor metastasis. Oncogene 29, 937-948 (2010).
48. Yang, J., Mani, S. A. & Weinberg, R. A. Exploring a new twist on tumor metastasis. Cancer Res. 66, 4549-4552 (2006).
49. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004).
50. Lee, T. K. et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 12, 5369-5376 (2006).
51. Yang, Z. et al. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem. Biophys. Res. Commun. 358, 925-930 (2007).
52. Carrio, M., Arderiu, G., Myers, C. & Boudreau, N. J. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res. 65, 7177-7185 (2005).
53. Makiyama, K. et al. Aberrant expression of HOX genes in human invasive breast carcinoma. Oncol. Rep. 13, 673-679 (2005).
54. Yang, W. J. et al. Dicer is required for embryonic angiogenesis during mouse development. J. Biol. Chem. 280, 9330-9335 (2005).
55. Suárez, Y., Fernández-Hernando, C., Pober, J. S. & Sessa, W. C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 100, 1164-1173 (2007).
56. Kuehbacher, A., Urbich, C., Zeiher, A. M. & Dimmeler, S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res. 101, 59-68 (2007).
57. Shilo, S., Roy, S., Khanna, S. & Sen, C. K. Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 471-477 (2008).
58. Fish, J. E. et al. MiR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15, 272-284 (2008).
59. Liu, B., Peng, X. C., Zheng, X. L., Wang, J. & Qin, Y. W. MiR-126 restoration down-regulate vEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 66, 169-175 (2009).
60. Hua, Z. et al. MiRNA-directed regulation of vEGF and other angiogenic factors under hypoxia. PLoS ONE 1, e116 (2006).
61. Chen, Y. & Gorski, D. H. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 111, 1217-1226 (2008).
62. Rhoads, K. et al. A role for Hox A5 in regulating angiogenesis and vascular patterning. Lymphat. Res. Biol. 3, 240-252 (2005).
63. Poliseno, L. et al. MicroRNAs modulate the angiogenic properties of HUvECs. Blood 108, 3068-3071 (2006).
64. Matsui, J., Wakabayashi, T., Asada, M., Yoshimatsu, K. & Okada, M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J. Biol. Chem. 279, 600-607 (2004).
65. Fasanaro, P. et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem. 283, 15878-15883 (2008).
66. Chow, T. F. et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J. Urol. 183, 743-751 (2010).
67. Yu, J. et al. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis and involved in cancer cell proliferation and invasion. Cancer Biol. Ther. 10, 1555-1576 (2010).
68. Li, H., Bian, C., Liao, L., Li, J. & Zhao, R. C. MiR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res. Treat. doi:10.1007/ s10549-010-0954-4.
69. Dews, M. et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 1060-1065 (2006).
70. Brennecke, J., Hipfner, D. R., Stark, A., Russell, R. B. & Cohen, S. M. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25-36 (2003).
71. Xu, P., vernooy, S. Y., Guo, M. & Hay, B. A. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr. Biol. 13, 790-795 (2003).
72. Cimmino, A. et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944-13949 (2005).
73. Calin, G. A. et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl Acad. Sci. USA 105, 5166-5171 (2008).
74. Park, M. J. et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. 62, 6318-6322 (2002).
75. Cmarik, J. L. et al. Differentially expressed protein PDCD4 inhibits tumor promoter-induced neoplastic transformation. Proc. Natl Acad. Sci. USA 96, 14037-14042 (1999).
76. Jansen, A. P., Camalier, C. E. & Colburn, N. H. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 65, 6034-6041 (2005).
77. Chen, Y. et al. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett. 272, 197-205 (2008).
78. Hiyoshi, Y. et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin. Cancer Res. 15, 1915-1922 (2009).
79. Lee, D. Y., Deng, Z., Wang, C. H. & Yang, B. B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl Acad. Sci. USA 104, 20350-20355 (2007).
80. Qin, W. et al. MiR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS ONE 5, e9429 (2010).
81. Gabriely, G. et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 28, 5369-5380 (2008).
82. Song, B. et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J. Exp. Clin. Cancer Res. 29, 29 (2010).
83. Huang, T. H. et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J. Biol. Chem. 284, 18515-18524 (2009).
84. Du, J. et al. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res. 19, 487-496 (2009).
85. Yang, H. et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433 (2008).
86. Ji, J. et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361, 1437-1447 (2009).
87. Qian, B. et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGFbeta1. Breast Cancer Res. Treat. 117, 131-140 (2009).
88. Camps, C. et al. Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340-1348 (2008).
89. Yamamoto, Y. et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14, 529-538 (2009).
90. Lin, S. L., Chiang, A., Chang, D. & Ying, S. Y. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14, 417-424 (2008).
91. Schaefer, A. et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126, 1166-1176 (2010).
92. Spahn, M. et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 127, 394-403 (2010).
93. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
94. Baffa, R. et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 219, 214-221 (2009).
95. veerla, S. et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124, 2236-2242 (2009).
96. Dyrskjøt, L. et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69, 4851-4860 (2009).
97. Hanke, M. et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. doi:10.1016/ j.urolonc.2009.01.027.
98. Jung, M. et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 13, 3918-3928 (2009).
99. Petillo, D. et al. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 35, 109-114 (2009).
100. Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
101. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007).
102. Krützfeldt, J. et al. Silencing of microRNAs in vivo with ?antagomirs?. Nature 438, 685-689 (2005).
103. vester, B. & Wengel, J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43, 13233-13241 (2004).
104. Elmén, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008).
105. Takeshita, F. et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18, 181-187 (2010).
106. Trang, P. et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29, 1580-1587 (2010).
107. Esquela-Kerscher, A. et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7, 759-764 (2008).
108. Kumar, M. S. et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl Acad. Sci. USA 105, 3903-3908 (2008).
109. Metias, S. M., Lianidou, E. & Yousef, G. M. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J. Clin. Pathol. 62, 771-776 (2009).
110. Hasemeier, B., Christgen, M., Kreipe, H. & Lehmann, U. Reliable microRNA profiling in routinely processed formalin-fixed paraffinembedded breast cancer specimens using fluorescence labelled bead technology. BMC Biotechnol. 8, 90 (2008).
111. Siebolts, U. et al. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J. Clin. Pathol. 62, 84-88 (2009).
112. Xi, Y. et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13, 1668-1674 (2007).
113. Mattie, M. D. et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006).
114. Szafranska, A. E. et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin. Chem. 54, 1716-1724 (2008).
115. Sturgeon, C. M. et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 54, e11-e79 (2008).
116. Cho, W. C. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6, 60 (2007).
117. vecchione, A. & Croce, C. Apoptomirs: small molecules have gained the license to kill. Endocr. Relat. Cancer 17, F37-F50 (2010).
118. Chan, S. Y. & Loscalzo, J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 9, 1072-1083 (2010).
119. Wang, S. & Olson, E. N. AngiomiRs-key regulators of angiogenesis. Curr. Opin. Genet. Dev. 19, 205-211 (2009).
120. Xiao, B. et al. Detection of miR-106a in gastric carcinoma and its clinical significance. Clin. Chim. Acta 400, 97-102 (2009).
121. Lee, J. W. et al. Altered microRNA expression in cervical carcinomas. Clin. Cancer Res. 14, 2535-2542 (2008).
122. Huang, Z. M. et al. MicroRNA expression profile in non-cancerous colonic tissue associated with lymph node metastasis of colon cancer. J. Dig. Dis. 10, 188-194 (2009).
123. Segura, M. F. et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl Acad. Sci. USA 106, 1814-1819 (2009).
124. Worley, L. A., Long, M. D., Onken, M. D. & Harbour, J. W. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 18, 184-190 (2008).
125. Garzia, L. et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 4, e4998 (2009).
126. Chang, K. W. et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J. Dent. Res. 87, 1063-1068 (2008).
127. Mees, S. T. et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann. Surg. Oncol. 16, 2339-2350 (2009).
128. Huang, X. H. et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol. Res. 39, 786-794 (2009).
129. Kitago, M., Martinez, S. R., Nakamura, T., Sim, M. S. & Hoon, D. S. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin. Cancer Res. 15, 2988-2994 (2009).
130. Nass, D. et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 19, 375-383 (2009).
131. Avissar, M., McClean, M. D., Kelsey, K. T. & Marsit, C. J. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 30, 2059-2063 (2009).
132. Markou, A. et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative realtime RT-PCR. Clin. Chem. 54, 1696-1704 (2008).
133. Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753-3756 (2004).
134. Laios, A. et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer 7, 35 (2008).
135. Satzger, I. et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 126, 2553-2562 (2009).
136. Greither, T. et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors associated with poorer survival. Int. J. Cancer 126, 73-80 (2010).
137. Ogawa, R. et al. Expression profiling of micro- RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med. Mol. Morphol. 42, 102-109 (2009).